Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ocular Therapeutix (OCUL) Long-Term Debt Repayments (2017 - 2021)

Historic Long-Term Debt Repayments for Ocular Therapeutix (OCUL) over the last 5 years, with Q2 2021 value amounting to $2.1 million.

  • Ocular Therapeutix's Long-Term Debt Repayments changed N/A to $2.1 million in Q2 2021 from the same period last year, while for Dec 2023 it was $2.1 million, marking a year-over-year change of. This contributed to the annual value of $26.1 million for FY2023, which is N/A changed from last year.
  • According to the latest figures from Q2 2021, Ocular Therapeutix's Long-Term Debt Repayments is $2.1 million.
  • Over the past 5 years, Ocular Therapeutix's Long-Term Debt Repayments peaked at $2.1 million during Q2 2021, and registered a low of $1.0 million during Q1 2018.
  • Moreover, its 3-year median value for Long-Term Debt Repayments was $1.5 million (2018), whereas its average is $1.6 million.
  • Within the past 5 years, the most significant YoY rise in Ocular Therapeutix's Long-Term Debt Repayments was 2084.62% (2018), while the steepest drop was 2084.62% (2018).
  • Quarter analysis of 3 years shows Ocular Therapeutix's Long-Term Debt Repayments stood at $1.3 million in 2017, then grew by 18.69% to $1.5 million in 2018, then skyrocketed by 35.06% to $2.1 million in 2021.
  • Its last three reported values are $2.1 million in Q2 2021, $2.1 million for Q1 2021, and $1.5 million during Q4 2018.